newsfilter
← Latest News
Earnings Call Transcripts·

Jefferies Global Healthcare Conference in London - IONIS PHARMACEUTICALS INC

I think we can get started. Hello, everyone. Welcome to the Jeffery's Illumina Healthcare Conference. My name is Albert Zhang. I'm an associate on Akash Tewari's team. Akash is running a little late from another meeting, but we have the pleasure here to have Dr. Brett Monia. Oh, Akash. I'm sorry about that, and thank you, Albert. Brett, great to have you, and apologies for the lateness. We're really looking forward to the discussion, why don't I hand it off to you for some intro remarks and we'll get started. Male Speaker 1 Yeah, happy to, Akash, thanks everybody. Thanks for the invitation, great to see all of you. We're excited about the future value creation potential for Ionis going forward. Ionist is completing the evolution to a fully integrated commercial stage biotechnology company, launching our own medicines. We are now in the process of launching three really important medicines wholly owned by Ionis today, products that have been approved just over the last year or two, Tringolza for severe hypertriglyceridemia for a multibillion-dollar market opportunity, Donzara for hereditary angioedema, a rare disease indication. That launch continues to go very well. And just recently, approval for a neurodegenerative indication called Alexander disease, Zanvastro, for that disease. That launch is now underway, being conducted by Ionis. Today we have seven products on the market, including those three, for eight disease indications. We have four medicines in phase three development, with more expected to reach phase three development next year, setting us up for a steady cadence of new medicines reaching the market, all of which have real, real breakthrough profiles for patients, for shareholders, and so on. So Ionis is very well positioned to deliver a steady case of medicines to drive value well into the future. Understood. So, Brett, let's start off with Tringles, and I think there's a lot of invest your attention on that. Surprising quarters, sometimes the surprises are good. Sometimes they're bad. But I want to start off with a question that almost sounds absurd sometimes, where you're like, because but we get it a lot and we think about it, which is, is this a quote unquote real market, right? And I think there's more nuance to that. It's more, is there enough urgency to really drive physician engagement out of the gate? Do doctors look at trigs and say, you know what, I've looked at this for a while. I'm not urgently looking at treating this. And how do you kind of narrow the scope to really identify people who are urgently going to get patients on Tringolza and convert them into kind of paid scripts? So I think you've learned more about the market, too, as you've entered. So what have you thought about initially and how have you refined that as you entered into the market? Yeah, happy to. So let me level set for everybody, first of all. Trigulza is indicated today for two diseases. One is familial chylomicronemia syndrome. That was launched last year, and that launched as a rare disease, and then which launched when it has gone very well. This year we expanded the indication for severe hypertriglyceridemia, which is not a rare diseas. It affects millions of people, people with high triglycerides, triglykerides that are well above normal that put them at high risk for various comorbidities. but most importantly is the risk of a potentially fatal acute pancreatitis attack. And if it's not fatal, it leads to destruction of the pancreas and all kinds of problems, diabetes and so on. Trigulza is the first FDA-approved medicine, now approved in Europe as of yesterday, for severe hypertriglyceridemia that not only has unprecedented reductions in triglycerides, but also for the first time demonstrating statistically significant reductions in acute pancreatitis. So it has outcome data. This affects, as I think I said, millions of people in major markets. What we're focused on, Akash, of course, initially are those high-risk patients, which are about a million in the U.S., probably equal in Europe, that are at high risk for acute pancreatitis because their triglycerides are so high that they're at higher risk or they have already had acute panreatitis events. And once you've had one event, the chances of a recurring potentially fatal event increases exponentially. That's been our initial focus. Your question is whether this is a real market or not. You said, I won't say the word you said. You said absurd. It's an absurd question. I think it's obvious. And I think that's the opinion of HCPs as well around the globe, that this is very, very high unmet medical need. And Trigulza is the first medicine to meaningfully address this disease indication. Now, we're in the early innings of the launch. We're three months into a launch. We're creating a new category, right? That requires extensive education. That requires HCPs to become familiar with a brand-new medicine that they probably don't have much familiarity unless they were prescribing for FCS in the past. It requires them to be educated on the criteria for prescribing their drug to patients. so they can get on the drug? Do they have to be on another triglyceride-lowering generic drug first? Will they have got to get their triglycyrides measured? Will the access process be easy, smooth, streamlined for them so that they don't have headaches and their office staff doesn't get blocked up with having to go through medical exceptions and those kinds of things? We're working through all that right now. What I can tell you is that we are 100% confident in the multibillion-dollar product opportunity for Tringolza, goals of, and that's based on tremendous HCP enthusiasm with intent to treat patients, a remarkably broad label that includes reductions in acute pancreatitis in the indication statement, despite the fact that that wasn't our primary endpoint. The FDA recognized that as being so important that they put it in the medication statement. What has been the biggest surprise to part of your question in the early part of the launch, three months into the launch only, I want to emphasize that, is that although there's been tremendous enthusiasm by the HCP community, particularly cardiologists, with intent to treat, they've been treating only a very small number of patients out of the gate to get familiarity with the drug, to get familiarity with the process, just to make sure that the access process isn't cumbersome. That's what we're focused on now, is to make that process is streamlined by working very closely with these HCPs so that they gain that familiarity very, very quickly. We're taking other initiatives, too, which we could talk about, like quick start programs. Quick start programs are something that we initiated right from the beginning, but we're now expanding. Why are we expanding it? us, we want to make sure that patients that get prescribed Tringol, they get on the drug as fast as possible because the experience by both the HCPs as well as the patients has been remarkably positive. And if we can get those patients while they work, while we work through an initial medical exception process, which takes longer with a new drug, a new class for payers, we can get them onto medicine as fast possible. That experience is going to translate to deeper and deeper prescriptions being written by physicians because the experience has been so positive. Understood. Now, I want to tackle this on multiple fronts. I think one of the things that is kind of a lesson for me too is, you know, a payer can say, I've given you broad access, but they can make it a pain to really get access to the medication, right? So if we look at some of your, you now, insurance policies right now, you're 100% right. Like above 550, history of pancreatitis. I mean, it's not like you look at the criteria in terms of being eligible and say, this is particularly onerous. It doesn't look like that. But then the nuance is, okay, well, then what do I need to actually get on Tringosa? Well, I need a try, maybe background therapies. I need make sure that I'm on an optimized fibrate or an optimized fish oil. And sometimes patients get on incretins, and then they'll, you know, they'll be at 700, they go to 500, and they'll say, well you know we've solved the problem, right? So there's this kind of false dynamic of broad access, but ease is a different thing. How much is your team working on, you know, really improving conversion time? Because, I mean, I think to your point, too, if you look at your clinical data, many of these patients tried background therapy. There's a reason why they're not controlled. But I don't think the plans necessarily recognize that. And they kind of give these doctors and patients, you have to run-through hoops, right? So do you think that is an issue, and is there a timeline to maybe improve that for Trigulzo? No question. We have a lot of activities underway to speed up the process from intent to treat, prescription writing, and covered patient. That's all going well. A couple of points I want to make to your questions. One is patients do have to be on a, have had to try a triglyceride-lowering agent to be eligible for Tringolza for payers, and not for the label, but for payors. But remember I mentioned those high-risk patients in my intro comments, that that's nearly a million people that are at very high risk for acute pancreatitis, though most of those patients are already on those generic drugs because they're in such bad condition, so we don't have to go through that hurdle. They're already on the medicines. For new patients that are new to just diagnosed, sure, they have to do that. They have to get through that process. That will take three to six months to go Through that process, but really we're focused on those high-risk patients, the majority of which are already on generic drugs ineffectively. Second, payer coverage. We've actually been very pleased with the progress we've made in getting Tringolza into formularies with payers today. After the first quarter of the launch, we had 34% of commercial lives covered, and those patients are being covered to label. That means that they're not being restricted to just the high-risk patient population or other segments of the patient population. They're being covered to label, which means if you have triglycerides 500 and above, regardless of history of acute pancreatitis, they're being covered. So we're very pleased with that process to date. That's going to grow. That coverage is going to increase this year, and it's going to increase next year. And next year, we expect to then have Medicare contracts in place. So this is moving in the right direction. We're very, very pleased where we're headed for this. What are we doing to speed up the process, to your question? You know, it's not unusual for cardiologists to take time to be able to get comfortable with a new medicine, a new category for treatment. One of the things that we understand and we've seen success based on is calling those docs more often, right? Getting in front of them and making sure that they understand the urgency to treat, the urgency to treat, not waiting for the next appointment by your patient and then measure their triglycerides and then get them off the treatment, but push those physicians to bring those patients in sooner, to get them on drug, to give them out of a risk for a potentially fatal acute pancreatitis attack. And the other thing we're doing is not just the push, but the pull, right? Patient education. Do you know your triglycide levels? Do you now that there's a medicine now that is available to treat effectively severely elevated triglycerides. That's through campaigns like digital, omni-channel, those kinds of things to get the patients, do you know your triglyceral rights? So there's a lot of learnings in the first few months of the launch, and I think we're making really good progress. Understood. And, you know, you talked about on the call, and even you alluded to this in your opening remarks, the Quick Start program. So can you help us define who are the patients where this quick start program really helps is this someone where they want to get on therapy a doctor's identified them they've gotten you know like they're already started the they're in the funnel let's put it that way and it's just taking a long time to get coverage is it uh that they have to get through um getting on background medication right like who's the patient who benefits from the quick start problem and can you kind of quantify with i know you haven't given exact numbers of people in the funnel, but even from a percentage perspective, the kind of demand that you've seen out of the gate, what percentage of that demand do you think you would have been able to convert to paid scripts if you actually had a quick start program in place out of gate? Well, one of the purposes, you know, the main goals of the quick start program, as I mentioned earlier, is to get patients onto medicine and get that experience, which has been uniformly positive as quickly as possible. The process, the experience on the process to get them on covered drug or to get him onto drug and then covered drug, that makes sure that process, they see that that process is very smooth, streamlined, and efficient, and also the clinical experience when you see your triglycerides plummet to, in many cases, to normal levels to get that process—get that experience in place, because that's going to just lead to deeper and deeper prescription writing right once they once a physician sees their patient is doing so well they're gonna write deeper I mean a lot of these physicians are managing 50 60 70 100 patients but they're only prescribing a handful until they get that experience so that's a big big component to the purpose of the quick start program is to get them that experience first because that experience is positive which patients it's gonna be the high-risk patients that will benefit the most I mean all patients will but those Those high-risk patients will benefit the most from the Quick Start program because the process to get to the treatment is faster because they're already on generic triglyceride-lowering drugs ineffectively, so we don't have to go through that hurdle. The Quick Start Program is only designed to offer a month or two of treatment before they get on to covered drugs, so it's not indefinite. It is a defined, finite period of time that they're going to stay on drug. And then we're seeing we're very pleased with the conversion to paid drug, the commercial drug, once they complete the quick start program. So it's still in the works. We have relaxed some of the criteria to get patients onto quick start programs faster, and we think that early signs are quite encouraging. Understood. And, you know, you've mentioned high risk, and, look, I'm in total agreement with you. I think there's a clear place for this drug. I've been surprised doctors wouldn't call if I was a cardiologist I would be calling up people and saying you need to get this under control but I do I feel like there is investor appetite how do you stratify high-risk right because you could say on label it's two to three million if we then cut it to let's say above 500 or you know 880 at risk you can get to let say a million right then you cut it to prior history of AP that gets to 50 to 80. When we've done some, you know, doc calls recently, I sense that docs stratified maybe even more, where it's not even just prior history of AP, it might be the how recently that AP event was, or were there multiple pancreatitis events, right? So when you think about, and it's Not like you have a massive cardiovascular sales force, you've been really efficient here. What have you learned in your early metrics about where there's been the highest rate of conversion, right? You go, again, like the 2 million, the 1 million, the 50 to 80,000 versus maybe it's recent prior AP or multiple prior AP. What did we learn out of the gate? That's exactly right. Physicians are absolutely prioritizing patients at the highest risk. In their view, what is the highest risk to get out to Trencolza first? And that's exactly what we expected, and that's why we focused on the high-risk patient population out of the gate to focus on for getting patients onto Trigulza. There are about up to nearly a million people in the U.S. that are high-risk for acute pancreatitis due to severely elevated triglycerides. To your point, Akash, what we're seeing, let me first say that we are seeing scripts across the board. We're seeing Scripps come in for patients that have no history of AP and are considered not high-risk. That means their triglycerides are between 500 and 799, up to 800. Above 800 or a history of acute pancreatitis, if you have a history of acute pancreatitis, you're at high risk. If your triglysterides are above 800, above 80 in particular, you are considered high-risk. We're seeing, of course, the majority of Scripps coming in for those high-risk patients, but we're seeing it across the board. But you're right, what we're, what were seeing prioritized are those patients that have had an acute pancreatitis event recently. It's also still top of mind for physicians, right? I saw that patient last month, they were in the ICU for two weeks because they had an acute pancreas event and there was nothing I could do. I need to get that patient on drugs. makes sense that they would do that first. Next would be those patients with a history of acute pancreatitis that still have their triglycerides through the roof, but they maybe have had acute pancreatitus events a couple of years ago. Those will be the next tier. Then there's the above 80 without a history without a mystery of acute pancreatosis. And then there's the more general population. This is really exciting market opportunity in that we know who the high-risk patients are that prescribers are going to treat most aggressively, and then we have the ability to expand through steps, eventually even maybe getting to that lower-risk patient population that has no history of acute pancreatitis, and that's what we're managing, but we are focused on the high risk patient population now, because we know that those are the priority for HCPs. No, no, no. But when you say high risk, you mean recent AP or the million? Both. Okay. Got it. Both. That's really up to the discretion of the physician. We think high risk means high risk. Right. For patients, whether they have had a recent AP event or whether they had one a year or two ago. Because the recurrence of AP is known to increase substantially. Leave that up to DHCP to decide. We're focused on high risk what we're seeing is that they are prioritizing those with a recent AP event. Okay, that's very helpful. Now, you know, it's not like a slower start market building. These are not foreign concepts in cardiovascular medicine, there's no doubt about it. I think for the investor community, though, and this would be really helpful, you know sometimes it's like, you'll talk to a company, they're like, we're sampling a ton out of the gate, right? So it's going to take time for us to convert, like we have a high gross the net right now. It's going to improve over a certain period of time. We have a sense of patients getting into the funnel, the ones that are kind of converting out. I think part of the frustration, you know, I think investors had on Q3 is we didn't really get a sketch of top of the funnel, in the funnel. And then, you Know, obviously, with the guidance is implied flat Q3 to Q4, it gives you just a lot of uncertainty going into 27 about really what the cadence is. So open-ended question, but really I'd love to get your take. Help us understand, A, is there an appetite to give more metrics going into Q4 and 27 so we can understand that conversion? Again, people understand gross to net and free drug. That happens all the time. But I think the concern is when we didn't get those metrics, the worry is it's a demand problem, not a conversion problem, if that makes sense. Yeah. So let me just level set by stating what the metrics were that we did provide, which I believe are very encouraging. And we will continue to provide these metrics at a minimum. First, we had more than 1,500 prescribers prescribe Tringolza in the first, by the end of September. That was three months after the SHTG approval. That's not bad. Second, we're beginning to see an uptick in those repeat prescribers, which is very important. As I mentioned before, they want to get experience with it, and then they're going to prescribe more deeply. 24% of prescriber are now, at the end of September, prescribing more than one script for their patients, and we're seeing that growing, so we'll continue to share that. We also provided payer coverage. 34% of commercial lives with SHTG were being covered by payers by the end of September. That's a pretty good start for payer coverage, and we'll continue to provide those metrics as that metric as well. Going forward, we're working through additional metrics we can provide. We're 100% committed to providing as much information as we can to lend confidence that this launch, how this launch is going, to understand how this lunch is going and to provide confidence that the launch is gonna go well. We're still creating a brand new market and a new sector for treatment is gonna require education and experience for this to really accelerate. We're pulling all the levers possible to make sure that happens. Understood. And by the way, I also will echo, sometimes too much is never a good thing either. But I think the other question is really into 27. You did say on the call, 27 is going to be an important growth year for Trinculsa. Now, I mean, if you look at kind of consensus estimates going into next year, this is obviously pre the guidance cut, there was a big number, there is a big step up. And I think there was general sense, this is not a traditional cardiovascular launch. This is more of a almost like ATTR, like faster launch out of the gate. an orphan cardiovascular launch in some ways. And I know everyone kind of struggles with the label, right? Because high risk and then there's a target group. I'd love to get your take. When we think about 2027 and we think about characterizing SHGG in the context of other CV launches, right? Does this feel more like an Entresto or PCSK9? Or does this feel something more akin to, you know, an orphan cardiovascular launch where there's faster uptake out of the gate, and it's more kind of plug and play. Yeah, well, you said it, Akash. 2026 is going to be a very important year for Tringolza. We're excited about it, and we think that this is going to be the year in which we see meaningful growth in the launch for Trangolza We still have a lot of work to do, to do all the things I already said, to build the market, to build experience, to build education, and we're taking all the steps we need to do that. We have not been able to find a good analog in the cardiovascular space that we can say, hey, that looks like an expectation for a Tringosal launch going forward. We're still building the market. As we understand and we start to see things come into place, like a broader adoption and prescribing by HCPs, deeper prescribing by HCCs, payer coverage for Tringolza, continuing to increase Medicare, coming on board, and so forth. I think we'll be able to provide more metrics and a better understanding if there is an analog out there today. What we are 100% confident in is that this is a multi-billion dollar product opportunity and Tringulza is the first to market to deliver the treatment that these patients need. And we're pulling all the stops to make sure that Trigulza maximizes value for all stakeholders. Understood. We're out of time, and it's a shame because I know you have so much going on within Ionis, but I really do appreciate the time. Wonderful discussion. Thanks, Josh. Thank you. Have a great day.

Company
IONIS PHARMACEUTICALS INC
Keywords
IONIS PHARMACEUTICALS INC